NewsRelease
PatentApplication Describes HemoVoid™ To Uncover Proteomic Changesfrom Stored Red Cells
MONMOUTHJUNCTION, NJ, January 25, 2019 -- BiotechSupport Group reports on a patent application describing thesimplicity and efficiency of their hemoglobin depletion technologyfor human stored red blood cells. The citation is:
Rosin-Arbesfeld,Rina, and Ronen SIMAN-TOV. "Articleof manufacture and methods for increasing survival of red bloodcells." U.S.Patent Application No. 15/739,857.
Thepatent application describes anex - vivo method of increasing survival of red blood cells (RBCs).The method comprises contacting the RBCs with an activator of the non- canonical Wnt pathway, which results in actin polymerization,thereby increasing survival of RBCs. The invention’s descriptionstates “The Haemolysates were enriched with over 95 % hemoglobin.For hemoglobin depletion,the hemoglobindepletion kit of HemoVoid … was used”. Upon depletion ofhemoglobin, a reduction in cytoplasmic actin levels was observed.Also the patent application describes a method of storing RBCs andtreating a medical condition associated with RBC cytoskeleton /membrane disease.
“Thereis great interest in understanding the proteomic changes in red cellsupon storage. As red cells are enucleated, there are no cellularmechanisms to produce new proteins so changes occur at thepost-translational level. As this patent application describes,proteomic analysis is a very productive way to uncover thoseimportant changes. I am pleased that our HemoVoid™ product wasquite useful for that purpose” states Swapan Roy, Ph.D., Presidentand Founder of Biotech Support Group.
Formore information onHemoVoid™,visit:
https://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm
Formore information on all of our Hemoglobin Removal Products, visit:
https://www.biotechsupportgroup.com/Articles.asp?ID=452
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ foralbumin depletion, Cleanascite™for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobinremoval, and NuGel™ for functional proteomics. From theseinnovations, the company has acquired knowledgebase and biomarkerintellectual property assets that support discoveries of proteinmarkers from blood, with special emphasis on early detection andpersonalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com
Contact:
Matthew Kuruc
732-274-2866
[email protected]